Ireland

The content featured in the below tabs is intended for the general public in Ireland and is created in-line with the IPHA code. All links featured in the top navigation bar fall under the global Sanofi website and the content found on these pages may refer to medical processes and regulations which can be different from those in Ireland. As a result, the medical information provided in the top navigation bar may not be appropriate for use in Ireland.

Our presence

For over 100 years we have been dedicated to making healthcare solutions. We have been doing this work in Ireland for over 20 years.

Our purpose

In Ireland, we work every day to serve those with health needs locally and around the world. We combine science innovation with dedication and determination to champion better health outcomes for patients. This pursuit of progress, supported by data and digital technologies, drives us to learn and grow. To push our limits, together.

Our work

We develop and manufacture healthcare solutions within many therapeutic areas: consumer self-care, cardiovascular disease, diabetes, multiple sclerosis, thrombosis, rare diseases, type 2 inflammation (e.g. atopic dermatitis) and vaccines.

Report a side effect

Please note that we cannot provide medical advice on your symptoms. If you are concerned about your personal health or condition(s), have a medical issue or symptoms, or they worsen, please contact your doctor or healthcare provider.

You can also report side effects directly to Sanofi on IEPharmacovigilance@sanofi.com or + 353 1 403 5600.

You can contact our medical information team for further information at IE-Medicalinformation@sanofi.com or + 353 1 403 5600.

Reporting to the Irish Health Authority

Suspected side effects should be reported to the Health Products Regulatory Authority (HPRA) at  www.hpra.ie (information about reporting side effects).

Valproate educational materials

These materials contain important information about the risks associated with valproate (Epilim▼) in female children and women of childbearing potential and pregnant women. They were developed in agreement with the Health Products Regulatory Authority (HPRA) and are available to healthcare professionals and patients.

▼This medicinal product is subject to additional monitoring.

MAT-IE-2300559 (v1.0)      January 2024